Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Gedeon Richter Sees Profit Jump By 40%

A strong tailwind from antipsychotic drug Vraylar helped Hungary’s Gedeon Richter to post a 40% leap in 2019 net profit. Analysts see more upside ahead for eastern Europe’s largest drugmaker.

Sales & Earnings Strategy

Sun Finds US ‘Challenging’

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Sales & Earnings Strategy

The Factory Floor: Biocon, Indoco, Strides And Lupin Line Up For Inspection

Biocon Pharma’s solid-dosage plant has received FDA inspection approval but its parent company was not so lucky, with one of its sites getting hit with five observations. Indoco, Strides, and Lupin were also in the regulatory spotlight while MedPharm has moved into a new, expanded facility and Coripharma has signed a packaging deal with Stada.

Manufacturing Compliance

US Sales Boost Ajanta

India’s Ajanta Pharma has announced what analysts called “blowout” third-quarter numbers following a string of weaker quarterly performances.

Sales & Earnings Strategy

FDA Updates ANDA Prioritization Policy

The US Food and Drug Administration has announced changes to how ANDAs are prioritized for review as it seeks to speed patient access to more affordable generic drugs and increase competition.

Regulation United States

Beximco Sees Profit Jump By A Sixth

Bangladesh’s biggest pharmaceutical company, Beximco Pharmaceuticals, has posted a 16.7% jump in after-tax profit in its financial first half, powered by double-digit domestic and export revenue growth.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register